Stocktoria
TG THERAPEUTICS, INC. TGTX
TG THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M | $152,000 | $152,000 | $152,000 | $152,000 | $152,000 |
| R&D expense | $160.2M | $94.3M | $76.2M | $125.4M | $222.6M | $165.9M | $154.2M | $159.4M | $102.5M | $69.2M |
| SG&A expense | $232.0M | $154.3M | $122.7M | $95.5M | $128.1M | $107.8M | $15.0M | — | — | — |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M | -$273.6M | -$169.1M | -$174.4M | -$118.7M | -$79.0M |
| Interest expense | — | — | $12.6M | $10.2M | $5.6M | $6.3M | $5.3M | $877,000 | $845,000 | — |
| Income tax | -$339.8M | $2.2M | $390,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $447.2M | $23.4M | $12.7M | -$223.8M | -$348.1M | — | — | — | — | — |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | — | — | — | — |
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M | -$214.5M | -$132.8M | -$128.9M | -$93.8M | -$61.6M |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M | -$214.9M | -$132.9M | -$129.0M | -$93.8M | -$61.9M |
| Cash & equivalents | $79.1M | $179.9M | $92.9M | $102.3M | $298.9M | $553.4M | $112.6M | $42.0M | $56.7M | $25.0M |
| Inventory | $125.6M | $110.5M | $39.8M | $0 | — | — | — | — | — | — |
| Total assets | $1.1B | $577.7M | $329.6M | $193.6M | $379.6M | $625.6M | $163.0M | $83.6M | $97.4M | $54.8M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M | $106.3M | $124.4M | $59.6M | $30.4M | $18.9M |
| Shareholders' equity | $648.0M | $222.4M | $160.5M | $58.6M | $237.2M | $519.4M | $38.6M | $24.0M | $67.0M | $35.9M |
Growth · year-over-year · Revenue CAGR 151.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +87.3% | +40.8% | +8290.0% | -58.4% | +4300.7% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Net income growth | +1812.4% | +84.5% | — | — | — | — | — | — | — | — |
| EPS growth | +1746.7% | +66.7% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.